Lecanemab is the first drug to change the course of Alzheimer’s disease, but two deaths during its clinical trial have raised questions about the drug’s safety.
Senior Science Reporter, Tori Blakeman, met with Zoology professor, Matthew Cobb, to discuss the applications and concerns surrounding this revolutionary genetic technology
